TGF-β-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells

European Journal of Immunology

Volumn 29, Issue 3, 1999, Pages 1032-1040

  Münz, Christian ^a   Naumann, Ulrike ^a   Grimmel, Cornelia ^a   Rammensee, Hans Georg ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Decorin; Glioma; Immunotherapy; TGF ; Tumor immunogenicity

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DECORIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0344141210     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-4141(199903)29:03<1032::aid-immu1032>3.0.co;2-w     Document Type: Article

References (19)

1. Roszman, T., Elliott, L. and Brooks, W., Modulation of T-cell function by gliomas. Immunol. Today 1991. 12: 370-374.
2. Weller, M. and Fontana, A., The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Rev. 1995. 21: 128-151.
3. 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur. J. Immunol. 1994. 24: 1293-1300.
4. Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L. and Rowley, D. A., A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 1990. 87: 1486-1490.
5. Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., Annunziata, N. and Doetschman, T., Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992. 359: 693-699.
6. Marzo, A. L., Fitzpatrick, D. R., Robinson, B. W. and Scott, B., Antisense oligonucleotides specific for transforming growth factor ß2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res. 1997. 57: 3200-3207.
7. Wu, S., Theodorescu, D., Kerbel, R. S., Willson, J. K. V., Mulder, K. M., Humphrey, L. E. and Brattain, M., TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J. Cell Biol. 1992. 116: 187-196.
8. Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dorries, R., Schlingensiepen, K. H. and Brysch, W., The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 1993. 78: 944-951.
9. Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I. and Sobol, R. E., Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA 1996. 93: 2909-2914.
10. Ständer, M., Naumann, U., Dumitrescu, L., Heneka, M., Löschmann, P. A., Gulbins, E., Dichgans, J. and Weller, M., Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Therapy 1998. 5: 1137-1144.
11. Shimizu, Y. and De Mars, R., Production of human cells expressing individual transferred HLA-A, -B, -C genes using an HLA-A, -B, -C null human cell line. J. Immunol. 1989. 142: 3320-3328.
12. Yamaguchi, Y., Mann, D. M. and Ruoslahti, E., Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990. 346: 281-284.
13. Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D. and Ruoslahti, E., Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992. 360: 361-364.
14. Isaka, Y., Brees, D. K., Ikegaya, K., Kaneda, Y., Imai, E., Noble, N. A. and Border, W. A., Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med. 1996. 2: 418-423.
15. Santra, M., Skorski, T., Calabretta, B., Lattime, E. C. and lozzo, R. V., De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. USA 1995. 92: 7016-7020.
16. De Luca, A., Santra, M., Baldi, A., Giordano, A. and lozzo, R. V., Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 1996. 271: 18961-18965.
17. Teicher, B. A., Maehara, Y., Kakeji, Y., Ara, G., Keyes, S. R., Wong, J. and Herbst, R., Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. Int. J. Cancer 1997. 71: 49-58.
18. Grimm, E. A., Crump, W. L.3d., Durett, A., Hester, J. P., Lagoo Deenadalayan, S. and Owen-Schaub, L. B., TGF-β inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol. Immunother. 1988. 27: 53-58.
19. Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M. and Forbes, J. T., Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Invest. 1993. 92: 2569-2576.